Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
This study has been completed.
Study NCT00005951 Information provided by National Cancer Institute (NCI)
First Received: July 5, 2000 Last Updated: November 22, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Central Nervous System Neoplasms
Glioma
Nervous System Neoplasms
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Nervous System Diseases
Neuroectodermal Tumors
Interventions listed in this trial
irinotecan hydrochloride
temozolomide
Additional drug interventions recognized in this trial
Camptothecin
Irinotecan
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Duke University
National Cancer Institute (NCI)
Back to top of Main Content
